Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments intended to boost prescriptions. Recently, Pfizer found itself in the ...
Armed with dual approvals in migraine treatment and prevention, Biohaven Pharmaceuticals’ blockbuster-in-waiting Nurtec ODT continued to roll in 2021, ginning up nearly $500 million in revenue. Nurtec ...
Pfizer grabbed a stake in Biohaven Pharmaceuticals last fall when it partnered with the company on the commercialization of oral migraine drug Nurtec. Now the pharmaceutical giant is buying the rest ...
NEW HAVEN, Conn., Jan. 6, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, ...
The approval of medicines called “CGRP antagonists” has led to big changes in how migraines are managed. These medicines work in a different way than older medicines to treat or prevent migraine. The ...
- Insurance Coverage of Nurtec ODT Now Totals 96 Percent of Commercial Lives or Approximately 255 Million Lives Covered in All Channels - Nurtec ODT Label Expanded to include Lactation Data in the ...
(WHTM) – Pfizer is recalling more than four million Nurtec ODT tablet packs that do not meet child-resistant packaging requirements, creating a potential poisoning risk for children. According to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback